FDA Panel Narrowly Supports BioMimetic's Augment Synthetic Bone Graft

FDA's Orthopedic and Rehabilitation Devices advisory panel narrowly supported approval of BioMimetic Therapeutics’ Augment synthetic bone graft May 12.

More from Archive

More from Medtech Insight